Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 04; 18(4):257-265.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Female
Humans
Imidazoles
Male
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein Kinase Inhibitors
Pyridazines
Treatment Outcome

authors with profiles

ELIAS JOSEPH JABBOUR
HAGOP M KANTARJIAN